Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants
Antimicrobial Agents and Chemotherapy · 01.07.2026 · 70 (7)
DOI: 10.1128/aac.00282-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.07.2026. Verfasst von Jun Morita und 7 weiteren Autor:innen. Beteiligte Einrichtung: R&D Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Meiji Seika Pharma Co., Ltd..
Abstract (Originalsprache)
We conducted an open-label study to assess the pharmacokinetics, safety, and tolerability of nacubactam—a β-lactamase inhibitor—administered alone or in combination with β-lactam antibiotic. Japanese healthy male participants received a single dose of nacubactam 2 g on Day 1, a single dose of β-lactam antibiotic (cefepime 2 g, aztreonam 2 g, meropenem 2 g, and piperacillin 4 g in Cohorts 1, 2, 3, and 4, respectively) on Day 3, and the combination of nacubactam and β-lactam antibiotic on Day 5. The study drugs were intravenously administered over 60 min. A total of 32 participants (8 in each cohort) were enrolled in the study. All participants completed the study and were included in the analysis. Exposures to nacubactam or β-lactam antibiotic (maximum plasma concentration [ C max ], area under the plasma concentration-time curve from time zero to the last quantifiable time [AUC 0−t ], and AUC from time zero to infinity [AUC 0−∞ ]) were similar between the treatment periods (monotherapy vs combination therapy) in all cohorts. Coadministration of nacubactam and β-lactam antibiotic did not affect the pharmacokinetic profile of nacubactam or β-lactam antibiotic with the 90% confidence intervals for the geometric least squares mean ratios (combination therapy/monotherapy) of C max , AUC 0−t , and AUC 0−∞ contained within the equivalence range of 0.80 to 1.25 for all study drugs. Nacubactam and β-lactam antibiotics were well tolerated. All treatment emergent adverse events were mild in severity and resolved without treatment. Our results support the further clinical development of nacubactam coadministered with these β-lactam antibiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R&D Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
- Souseikai Sumida Hospital, Tokyo, Japan.
- Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
ORCID-Profile: Jun Morita
Förderung
- Meiji Seika Pharma Co., Ltd.
Zitieren
APA
Morita, J., Sato, H., Sumiya, M., Takaya, R., Ishiwata, K., Matsumoto, S., Yonemura, T., & Kumagai, Y. (2026). Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants. Antimicrobial Agents and Chemotherapy, 70(7). https://doi.org/10.1128/aac.00282-26
Vancouver
Morita J, Sato H, Sumiya M, Takaya R, Ishiwata K, Matsumoto S, et al. Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants. Antimicrobial Agents and Chemotherapy. 2026;70(7). doi:10.1128/aac.00282-26
BibTeX
@article{Morita2026,
author = {Morita, Jun and Sato, Hiroki and Sumiya, Masayo and Takaya, Risako and Ishiwata, Kazuya and Matsumoto, Shogo and Yonemura, Takuma and Kumagai, Yuji},
title = {Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {7},
doi = {10.1128/aac.00282-26}
}
EUVIMED